Neogen Corp
NEOG
In Vitro & In Vivo Diagnostic Substances
Mkt Cap
$2.926BPE
1868.61Debt
$1.79BCash
$161.4MEV
$4.555BFCF
-$13.19MP/E Ratio
1868.61Debt
$1.79BCash
$161.4MEV
$4.555BFCF
-$13.19MCharts data: {"Earnings":[{"time":"2015-05-30","value":33526000},{"time":"2016-05-30","value":36538000},{"time":"2017-05-30","value":43793000},{"time":"2018-05-30","value":63145000},{"time":"2019-05-30","value":60176000},{"time":"2020-05-30","value":59475000},{"time":"2021-05-30","value":60882000},{"time":"2022-05-30","value":48307000},{"time":"2023-05-30","value":-22870000}],"Sales":[{"time":"2015-05-30","value":283074000},{"time":"2016-05-30","value":321275000},{"time":"2017-05-30","value":361594000},{"time":"2018-05-30","value":402252000},{"time":"2019-05-30","value":414186000},{"time":"2020-05-30","value":418170000},{"time":"2021-05-30","value":468459000},{"time":"2022-05-30","value":527159000},{"time":"2023-05-30","value":822447000}],"Net Margins":[{"time":"2015-05-30","value":0.11843546210531522},{"time":"2016-05-30","value":0.11372811454361528},{"time":"2017-05-30","value":0.1211109697616664},{"time":"2018-05-30","value":0.15697870986346868},{"time":"2019-05-30","value":0.14528738296320975},{"time":"2020-05-30","value":0.14222684554128703},{"time":"2021-05-30","value":0.12996228058378642},{"time":"2022-05-30","value":0.09163648918068362},{"time":"2023-05-30","value":-0.027807262960409605}],"Assets":[{"time":"2015-05-30","value":392181000},{"time":"2016-05-30","value":451715000},{"time":"2017-05-30","value":528409000},{"time":"2018-05-30","value":618009000},{"time":"2019-05-30","value":695740000},{"time":"2020-05-30","value":797182000},{"time":"2021-05-30","value":920192000},{"time":"2022-05-30","value":992929000},{"time":"2023-05-30","value":4554432000}],"Stockholders Equity":[{"time":"2015-05-30","value":350974000},{"time":"2016-05-30","value":404198000},{"time":"2017-05-30","value":471757000},{"time":"2018-05-30","value":560175000},{"time":"2019-05-30","value":637899000},{"time":"2020-05-30","value":725177000},{"time":"2021-05-30","value":840377000},{"time":"2022-05-30","value":887374000},{"time":"2023-05-30","value":3134217000}],"ROE":[{"time":"2015-05-30","value":0.09552274527457874},{"time":"2016-05-30","value":0.09039629092672403},{"time":"2017-05-30","value":0.09282957115633685},{"time":"2018-05-30","value":0.11272370241442406},{"time":"2019-05-30","value":0.09433468307678802},{"time":"2020-05-30","value":0.08201445991806139},{"time":"2021-05-30","value":0.07244605694825061},{"time":"2022-05-30","value":0.054438151219215344},{"time":"2023-05-30","value":-0.007296878295280767}],"ROA":[{"time":"2015-05-30","value":0.13544256351021594},{"time":"2016-05-30","value":0.12482649458176062},{"time":"2017-05-30","value":0.12776277466886446},{"time":"2018-05-30","value":0.12217945046107742},{"time":"2019-05-30","value":0.11159628596889642},{"time":"2020-05-30","value":0.09821722015800657},{"time":"2021-05-30","value":0.0835499547920434},{"time":"2022-05-30","value":0.06063575542662164},{"time":"2023-05-30","value":0.008237031533240588}]}
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed producers and processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
![QDEL Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>QDEL</text></svg>){kind=small}
In the chart Earnings are multiplied by this value.
Earnings Growth -8.5%
Earnings Stability -2.9%
Competitiveness and MOAT
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
| Years | 05-2015 | 05-2016 | 05-2017 | 05-2018 | 05-2019 | 05-2020 | 05-2021 | 05-2022 | 05-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 12% | 11% | 12% | 16% | 15% | 14% | 13% | 9.2% | -2.8% | 0.17% |
| ROA | 14% | 12% | 13% | 12% | 11% | 9.8% | 8.4% | 6.1% | 0.82% | 1.5% |
| ROE | 9.6% | 9% | 9.3% | 11% | 9.4% | 8.2% | 7.2% | 5.4% | -0.73% | 0.05% |
What is the average Net Margin?
The average Net Margin over the past 5 years is +10.64%.
What is the trend of Net Margin?
The trend of Net Margin over the past 5 years is -3.13%.
What is the average Return on Assets (ROA)?
The average ROA over the past 5 years is +8.07%.
What is the trend of Return on Assets (ROA)?
The trend of ROA over the past 5 years is -2.11%.
What is the average Return on Equity (ROE)?
The average ROE over the past 5 years is +6.81%.
What is the trend of Return on Equity (ROE)?
The trend of ROE over the past 5 years is -2.08%.
Safety & Stabiliy
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
| Years | 05-2015 | 05-2016 | 05-2017 | 05-2018 | 05-2019 | 05-2020 | 05-2021 | 05-2022 | 05-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt FCF | - | 0.11 | - | - | - | - | - | 0.00 | -72.79 | -135.74 |
| Debt Equity | 0.01 | 0.01 | - | - | - | - | - | 0.00 | 0.57 | 0.57 |
| MIN | ||||||||||
| Graham Stability | - | - | - | 100% | 100% | 100% | 100% | 80% | -41% | -41% |
What is the Debt/FCF?
The Debt/FCF trailing twelve month is -135.74.
What is the trend of Debt/FCF?
The trend of Debt/FCF over the past 5 years is -72.79.
What is the Graham’s Stability?
Graham’s Stability measure stands at -0.41.
Growth
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
| Years | 05-2016 | 05-2018 | 05-2020 | 05-2022 | Trend |
|---|---|---|---|---|---|
| Revenue | 14% | 15% | 25% | 56% | 3.5% |
| Net Income | - | - | - | - | -6% |
| Stockholders Equity | 34% | 41% | 63% | 250% | 19% |
| FCF | - | - | - | - | -6.5% |
What is the 5 year Revenue CAGR?
The Revenue CAGR over the past 5 years is +15.38%.
What is the trend of Revenue growth?
The trend of Revenue growth rate over the past 5 years is +3.55%.
What is the 5 year Earnings CAGR?
The Earnings CAGR over the past 5 years is -.
What is the trend of Earnings growth?
The trend of Earnings growth rate over the past 5 years is -6.04%.
What is the 5 year Equity CAGR?
The Equity CAGR over the past 5 years is +41.11%.
What is the trend of Equity growth?
The trend of Equity growth rate over the past 5 years is +19.07%.
What is the 5 year FCF CAGR?
The FCF CAGR over the past 5 years is -.
What is the trend of FCF growth?
The trend of FCF growth rate over the past 5 years is -6.48%.